Literature DB >> 28156211

Dual time point method for the quantification of irreversible tracer kinetics: A reference tissue approach applied to [18F]-FDOPA brain PET.

I Lopes Alves1, Sanne K Meles2, Antoon Tm Willemsen1, Rudi A Dierckx1, Ana M Marques da Silva3, Klaus L Leenders2, Michel Koole4.   

Abstract

The Patlak graphical analysis (PGAREF) for quantification of irreversible tracer binding with a reference tissue model was approximated by a dual time point imaging approach (DTPREF). The DTPREF was applied to 18 [18F]-FDOPA brain scans using the occipital cortex as reference region (DTPOCC) and compared to both PGAOCC and striatal-to-occipital ratios (SOR). Pearson correlation analysis and Bland-Altman plots showed an excellent correlation and good agreement between DTPOCC and PGAOCC, while correlations between SOR and PGAOCC were consistently lower. Linear discriminant analysis (LDA) demonstrated a similar performance for all methods in differentiating patients with Parkinson's disease (PD) from healthy controls (HC). Specifically for [18F]-FDOPA brain imaging, these findings validate DTPOCC as an approximation for PGAOCC, providing the same quantitative information while reducing the acquisition time to two short static scans. For PD patients, this approach can greatly improve patient comfort while reducing motion artifacts and increasing image quality. In general, DTPREF can improve the clinical applicability of tracers with irreversible binding characteristics when a reference tissue is available.

Entities:  

Keywords:  Dual time point imaging; Parkinson’s disease; Patlak graphical analysis; [18F]-FDOPA; positron emission tomography

Mesh:

Substances:

Year:  2016        PMID: 28156211      PMCID: PMC5584692          DOI: 10.1177/0271678X16684137

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  28 in total

1.  A reversible tracer analysis approach to the study of effective dopamine turnover.

Authors:  V Sossi; D J Doudet; J E Holden
Journal:  J Cereb Blood Flow Metab       Date:  2001-04       Impact factor: 6.200

Review 2.  Standards for PET image acquisition and quantitative data analysis.

Authors:  Ronald Boellaard
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

Review 3.  Precision and accuracy considerations of physiological quantitation in PET.

Authors:  R E Carson
Journal:  J Cereb Blood Flow Metab       Date:  1991-03       Impact factor: 6.200

4.  Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data.

Authors:  Vesna Sossi; Raúl de La Fuente-Fernández; James E Holden; Doris J Doudet; Jess McKenzie; A J Stoessl; T J Ruth
Journal:  J Cereb Blood Flow Metab       Date:  2002-02       Impact factor: 6.200

5.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations.

Authors:  C S Patlak; R G Blasberg
Journal:  J Cereb Blood Flow Metab       Date:  1985-12       Impact factor: 6.200

6.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.

Authors:  C S Patlak; R G Blasberg; J D Fenstermacher
Journal:  J Cereb Blood Flow Metab       Date:  1983-03       Impact factor: 6.200

7.  Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with ¹⁸F-dopa brain PET in normal controls and patients with Parkinson's disease.

Authors:  Liane Oehme; Maria Perick; Bettina Beuthien-Baumann; Martin Wolz; Alexander Storch; Matthias Löhle; Birgit Herting; Jens Langner; Jörg van den Hoff; Heinz Reichmann; Jörg Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-07       Impact factor: 9.236

8.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

9.  Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls.

Authors:  Pekka Jokinen; Hans Helenius; Elina Rauhala; Anna Brück; Olli Eskola; Juha O Rinne
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

10.  The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG.

Authors:  Jörg van den Hoff; Liane Oehme; Georg Schramm; Jens Maus; Alexandr Lougovski; Jan Petr; Bettina Beuthien-Baumann; Frank Hofheinz
Journal:  EJNMMI Res       Date:  2013-11-23       Impact factor: 3.138

View more
  3 in total

1.  Physiological Whole-Brain Distribution of [18F]FDOPA Uptake Index in Relation to Age and Gender: Results from a Voxel-Based Semi-quantitative Analysis.

Authors:  Sinn-Rithy Toch; Sylvain Poussier; Emilien Micard; Marc Bertaux; Axel Van Der Gucht; Elodie Chevalier; Pierre-Yves Marie; Eric Guedj; Antoine Verger
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

2.  The role of dopamine dysregulation and evidence for the transdiagnostic nature of elevated dopamine synthesis in psychosis: a positron emission tomography (PET) study comparing schizophrenia, delusional disorder, and other psychotic disorders.

Authors:  Pak Wing Calvin Cheng; Wing Chung Chang; Gladys G Lo; Kit Wa Sherry Chan; Ho Ming Edwin Lee; Lai Ming Christy Hui; Yi Nam Suen; Yim Lung Eric Leung; Kai Ming Paul Au Yeung; Sirong Chen; Ka Fung Henry Mak; Pak Chung Sham; Barbara Santangelo; Mattia Veronese; Chi-Lai Ho; Yu Hai Eric Chen; Oliver D Howes
Journal:  Neuropsychopharmacology       Date:  2020-07-01       Impact factor: 7.853

3.  Astrocyte activation imaging with 11C-acetate and amyloid PET in mild cognitive impairment due to Alzheimer pathology.

Authors:  Michael Tran Duong; Yin Jie Chen; Robert K Doot; Anthony J Young; Hsiaoju Lee; Jenny Cai; Arun Pilania; David A Wolk; Ilya M Nasrallah
Journal:  Nucl Med Commun       Date:  2021-11-01       Impact factor: 1.690

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.